A Phase 2 Study of Stereotactic Radiosurgery and Standard Treatment in People With EGFR-Positive Lung Cancer That Has Spread to the Brain

Full Title

Purpose

Researchers want to see if giving stereotactic radiosurgery (SRS) after osimertinib is better than osimertinib alone for advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that metastasized (spread) to the brain. Their cancers have a mutation (change) in the EGFR gene, and they are taking or planning to take osimertinib.

SRS is a type of radiation therapy that targets a very small area of the body. Because it is so precise, SRS limits radiation exposure to the rest of the brain. Osimertinib and SRS are both standard treatments for brain metastases. Most people with NSCLC receive either osimertinib alone or SRS when they are first diagnosed with brain metastases.

If you join this study, you will be randomly assigned to take osimertinib alone or with SRS. Osimertinib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have NSCLC that has spread to the brain and has an EGFR mutation.
• Be taking or planning to take osimertinib.
• Not have had prior radiation therapy to the brain.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Luke Pike’s office at 212-639-8157.